CV Safety of Abaloparatide in Postmenopausal Osteoporosis CV Safety of Abaloparatide in Postmenopausal Osteoporosis

A new analysis provides insight into the cardiovascular safety profile of abaloparatide, a medication used to treat osteoporosis in postmenopausal women.Journal of Clinical Endocrinology & Metabolism
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news